Effects of intravitreal bevacizumab in Gram-positive and Gram-negative models of ocular inflammation.
J Daniel LafreniereJames T ToguriRishi R GuptaArif SamadDan M O'BrienJohn DickinsonAlan CruessMelanie E M KellyMark E SeamonePublished in: Clinical & experimental ophthalmology (2019)
Within a 6-hour window bevacizumab had anti-inflammatory actions that were distinct in both Gram-positive (PIU) and Gram-negative (EIU) models, respectively. Given our findings, this would suggest that bevacizumab may have utility as an adjunctive therapy to IVT antibiotics and vitrectomy in the management of exogenous endophthalmitis.